Alimera Sciences
ALIM

$5.57

0.36%

Market Cap: 292M

About: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Employees: 158

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

11% more funds holding

Funds holding: 35 [Q4 2023] → 39 (+4) [Q1 2024]

0.5% less ownership

Funds ownership: 92.01% [Q4 2023] → 91.51% (-0.5%) [Q1 2024]

10% less capital invested

Capital invested by funds: $208M [Q4 2023] → $187M (-$21.5M) [Q1 2024]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 4 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

8%

upside

Avg. target

$7

26%

upside

High target

$10

80%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

HC Wainwright & Co. Yi Chen	8%upside $6	Neutral Downgraded	25 Jun 2024
HC Wainwright & Co. Yi Chen	8%upside $6	Buy Reiterated	16 May 2024
Maxim Group Naz Rahman	80%upside $10	Buy Initiated	25 Mar 2024
HC Wainwright & Co. Yi Chen	8%upside $6	Buy Maintained	8 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ALIM published over the past 30 days

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

NEW YORK , July 2, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon th.

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.

Zacks Investment Research

Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals

Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.

Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders

Why Is Alimera Sciences (ALIM) Stock Up 77% Today?

Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.

Why Is Alimera Sciences (ALIM) Stock Up 77% Today?

ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.

ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals

See News Rankings